- CARBOGEN AMCIS has refinanced and enhanced its syndicated credit facilities, securing an additional CHF 40 million with an accordion feature for a further CHF 30 million.
- The enhanced funding will support the company’s long-term CDMO growth strategy, including investments in innovation, digital transformation, and sustainability.
CARBOGEN AMCIS, a subsidiary of Dishman Carbogen Amcis (DCAL.NS) and a global contract development and manufacturing organisation (CDMO), announced the successful refinancing and enhancement of its syndicated credit facilities led by UBS Switzerland AG.
The transaction provides access to an additional CHF 40 million, with an accordion feature enabling a further CHF 30 million, bringing the company’s total credit capacity to CHF 162,235,250 and EUR 50,000,000. According to Global Chief Financial Officer Harshil Dalal, this step marks an important milestone in supporting CARBOGEN AMCIS’s future growth plans.
Global Managing Director Arpit Vyas said the refinancing aligns with the company’s long-term strategy, which focuses on innovation, efficiency, and sustainability in the CDMO sector. “Our vision is to make significant advances in areas such as continuous flow chemistry, drug conjugation, and digital transformation, with a keen focus on artificial intelligence — all of which will enable the company to continue its organic growth,” he said.
Led by UBS Switzerland AG and supported by several financial institutions, the deal demonstrates strong confidence from banking partners in the company’s business model and growth trajectory.
Chief Executive Officer Stephan Fritschi added that the refinancing strengthens the company’s ability to invest in new technologies and infrastructure to advance its global contract manufacturing capabilities, following recent expansion of its Drug Product operations in France.
